Pharmaron, Inc. Sustainability Profile
Pharmaron, Inc., a leading global provider of integrated research and development services, is headquartered in the United States. Founded in 2004, the company has established a strong presence in key operational regions, including Europe and Asia, catering to the pharmaceutical and biotechnology industries. Pharmaron offers a comprehensive suite of services, including drug discovery, preclinical development, and clinical trial management, distinguished by its commitment to innovation and quality. The company has achieved significant milestones, positioning itself as a trusted partner for clients seeking to accelerate their drug development processes. With a robust portfolio of core services and a reputation for excellence, Pharmaron continues to enhance its market position, contributing to advancements in healthcare and therapeutic solutions worldwide.
DitchCarbon Score
How does Pharmaron, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pharmaron, Inc.'s score of 57 is higher than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Pharmaron, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Pharmaron Beijing Co., Ltd., which may influence its climate commitments and emissions reporting. As of now, Pharmaron, Inc. has not established any documented reduction targets or climate pledges. The absence of specific emissions data and reduction initiatives suggests that the company may still be in the early stages of developing its climate strategy. Given its relationship with Pharmaron Beijing Co., Ltd., any potential emissions data or climate commitments may be inherited from this parent organisation. However, no specific figures or targets have been provided in the available information. In summary, Pharmaron, Inc. is currently lacking detailed emissions data and defined climate commitments, reflecting a need for further development in its sustainability initiatives.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 48,007,050 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 267,941,280 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | 000,000,000 | 000,000,000 |
How Carbon Intensive is Pharmaron, Inc.'s Industry?
How Carbon Intensive is Pharmaron, Inc.'s Location?
Pharmaron, Inc.'s Scope 3 Categories Breakdown
Pharmaron, Inc.'s Scope 3 emissions, which increased by 5% last year and increased by approximately 5% since 2023, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 68% of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 55% of Scope 3 emissions.
Top Scope 3 Categories
Pharmaron, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Pharmaron, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
